Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pfizer Takes ‘Opportunistic’ Approach To Future Biosimilars

Company Sees 93% Growth In Biosimilars Business To $559m In Q2

Executive Summary

Pfizer reported double-digit growth in its biosimilars and sterile injectables segments, as the company indicated that it would take a more “opportunistic” approach to its biosimilars business in future. The company has also revised its overall 2021 financial guidance as it expects better numbers on the back of its COVID-19 vaccine business.

You may also be interested in...



Pfizer Warns Against Applying Generic Policies To Biosimilars

Pfizer’s biosimilars commercial lead, Roman Irsiegler, has set out his views on policy obstacles for biosimilars that need to be addressed if the market is to sustainably deliver on its potential.

Is The Bloom Off The Rose For Big Pharma And Biosimilars?

After a wave of big pharma interest in the biosimilars arena, originator enthusiasm for the sector appears to be waning – potentially opening up an opportunity for newcomers to compete on off-patent biologics.

Pfizer Quietly Chalks Up Another $2bn Year For Biosimilars

Despite annual sales that topped out at more than $2bn, Pfizer remains tight-lipped about its biosimilars interests as it looks towards a US launch this year of its Abrilada rival to Humira.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

GB151134

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel